Titan Pharmaceuticals Stock News

Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com

Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a

Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find pro

In last trading session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) saw 0.69 million shares changing hands with its beta currently measuring 0.78. Companys recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $11.19M. That closing price of TTNPs stock is Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? Read More »

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on []

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on [] The post Comparing Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) appeared first on ETF Daily News .

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 336,900 shares, a decline of 19.7% from the November 15th total of 419,700 shares. Based on an average daily volume of 183,400 shares, the short-interest ratio is presently 1.8 days. []

Vericel (NASDAQ:VCEL) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Profitability This table compares Vericel and Titan Pharmaceuticals net margins, return on equity and return on []

"U.S. Opioids Market, Drug Price, Sales and Clinical Trials Insight 2028 Report Highlights: U.S. Opioids Market Opportunity: > US$ 18,985.4 Million by 2028 U.S. Opioids Market Growth: 100% Absolute Growth Till 2028 U.S. Opioids Market Size Opportunity by Therapeutic Class Insight On Clinical

Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 455,000 shares, a growth of 20.3% from the October 14th total of 378,200 shares. Based on an average daily volume of 185,700 shares, the days-to-cover ratio is []

Titan Pharmaceuticals (NASDAQ:TTNP) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 5.9% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, []

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," for

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Dece

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.